EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Sources of pharmacokinetic and pharmacodynamic variability and clinical pharmacology studies of antiseizure medications in the pediatric population

Patricia D Maglalang iD, Jiali Wen iD, Christoph P Hornik iD, Daniel Gonzalez iD

Clinical and Translational Science · 2024-04 · 17 (4)

DOI: 10.1111/cts.13793 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 15.04.2024. Verfasst von Patricia D Maglalang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel H…. Hauptthemen laut MEDLINE: Pharmacology, Clinical, Epilepsy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple treatment options exist for children with epilepsy, including surgery, dietary therapies, neurostimulation, and antiseizure medications (ASMs). ASMs are the first line of therapy, and more than 30 ASMs have U.S. Food and Drug Administration (FDA) approval for the treatment of various epilepsy and seizure types in children. Given the extensive FDA approval of ASMs in children, it is crucial to consider how the physiological and developmental changes throughout childhood may impact drug disposition. Various sources of pharmacokinetic (PK) variability from different extrinsic and intrinsic factors such as patients' size, age, drug–drug interactions, and drug formulation could result in suboptimal dosing of ASMs. Barriers exist to conducting clinical pharmacological studies in neonates, infants, and children due to ethical and practical reasons, limiting available data to fully characterize these drugs' disposition and better elucidate sources of PK variability. Modeling and simulation offer ways to circumvent traditional and intensive clinical pharmacology methods to address gaps in epilepsy and seizure management in children. This review discusses various physiological and developmental changes that influence the PK and pharmacodynamic (PD) variability of ASMs in children, and several key ASMs will be discussed in detail. We will also review novel trial designs in younger pediatric populations, highlight the role of extrapolation of efficacy in epilepsy, and the use of physiologically based PK modeling as a tool to investigate sources of PK/PD variability in children. Finally, we will conclude with current challenges and future directions for optimizing the efficacy and safety of these drugs across the pediatric age spectrum.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pharmacology, ClinicalEpilepsyUnited StatesInfantInfant, NewbornHumansChildResearchSeizuresComputer Simulation

Autor:innen und Institutionen

  • Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Duke Clinical Research Institute, Durham, North Carolina, USA.
  • Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA.
  • Division of Clinical Pharmacology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

ORCID-Profile: Patricia D Maglalang, Jiali Wen, Christoph P Hornik, Daniel Gonzalez

Förderung

  • NIAID NIH HHS
  • NICHD NIH HHS

Zitieren

APA

Maglalang, P. D., Wen, J., Hornik, C. P., & Gonzalez, D. (2024). Sources of pharmacokinetic and pharmacodynamic variability and clinical pharmacology studies of antiseizure medications in the pediatric population. Clinical and Translational Science, 17(4). https://doi.org/10.1111/cts.13793

Vancouver

Maglalang PD, Wen J, Hornik CP, Gonzalez D. Sources of pharmacokinetic and pharmacodynamic variability and clinical pharmacology studies of antiseizure medications in the pediatric population. Clinical and Translational Science. 2024;17(4). doi:10.1111/cts.13793

BibTeX
@article{Maglalang2024,
  author = {Maglalang, Patricia D and Wen, Jiali and Hornik, Christoph P and Gonzalez, Daniel},
  title = {Sources of pharmacokinetic and pharmacodynamic variability and clinical pharmacology studies of antiseizure medications in the pediatric population},
  journal = {Clinical and Translational Science},
  year = {2024},
  volume = {17},
  number = {4},
  doi = {10.1111/cts.13793}
}
Kostenlos starten →